Keros Therapeutics Stock Alpha and Beta Analysis
| KROS Stock | USD 11.58 0.11 0.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Keros Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Keros Therapeutics over a specified time horizon. Remember, high Keros Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Keros Therapeutics' market risk premium analysis include:
Beta (0.22) | Alpha (1.70) | Risk 3.81 | Sharpe Ratio (0.21) | Expected Return (0.78) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Keros |
Keros Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Keros Therapeutics market risk premium is the additional return an investor will receive from holding Keros Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Keros Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Keros Therapeutics' performance over market.| α | -1.7 | β | -0.22 |
Keros Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Keros Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Keros Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Keros Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Keros Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Keros Therapeutics shares will generate the highest return on investment. By understating and applying Keros Therapeutics stock market price indicators, traders can identify Keros Therapeutics position entry and exit signals to maximize returns.
Keros Therapeutics Return and Market Media
The median price of Keros Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 11.59 with a coefficient of variation of 86.72. The daily time series for the period is distributed with a sample standard deviation of 14.76, arithmetic mean of 17.02, and mean deviation of 7.83. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Heres Why Keros Therapeutics is Poised for a Turnaround After Losing -39.17 percent in 4 Weeks | 01/16/2025 |
2 | KEROS ALERT Bragar Eagel Squire, P.C. is Investigating - GlobeNewswire | 01/24/2025 |
3 | Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 | 01/28/2025 |
4 | Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compounds Potential as a Therapeutic... | 02/06/2025 |
5 | Acquisition by Rovaldi Christopher of 60000 shares of Keros Therapeutics subject to Rule 16b-3 | 02/18/2025 |
6 | Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results | 02/26/2025 |
7 | Keros Therapeutics stock target cut to 40 at H.C. Wainwright - Investing.com | 02/27/2025 |
8 | Keros Therapeutics, Inc. Receives Consensus Rating of Moderate Buy from Analysts - MarketBeat | 03/03/2025 |
9 | Acquisition by Knowles Julius of 10000 shares of Keros Therapeutics at 46.31 subject to Rule 16b-3 | 03/07/2025 |
About Keros Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Keros or other stocks. Alpha measures the amount that position in Keros Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Days Sales Outstanding | 2.6K | 281.92 | 267.83 | PTB Ratio | 4.37 | 1.04 | 0.99 |
Keros Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Keros Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Keros Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Keros Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Keros Therapeutics. Please utilize our Beneish M Score to check the likelihood of Keros Therapeutics' management manipulating its earnings.
| 1st of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Keros Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.